(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 15.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.
Mannkind's revenue in 2025 is $313,787,000.On average, 11 Wall Street analysts forecast MNKD's revenue for 2025 to be $106,556,458,210, with the lowest MNKD revenue forecast at $95,394,453,495, and the highest MNKD revenue forecast at $124,633,685,652. On average, 11 Wall Street analysts forecast MNKD's revenue for 2026 to be $130,222,364,766, with the lowest MNKD revenue forecast at $99,757,922,188, and the highest MNKD revenue forecast at $158,408,345,859.
In 2027, MNKD is forecast to generate $146,051,837,752 in revenue, with the lowest revenue forecast at $111,343,683,891 and the highest revenue forecast at $190,457,271,087.